SKF-77,434

From WikiMD's WELLNESSPEDIA

SKF-77,434 is a drug that acts as a selective D1 receptor partial agonist, and has been researched for potential use in the treatment of Parkinson's disease. It is structurally related to the more well-known drug Fenoldopam, but has a different mechanism of action.

Pharmacology[edit]

SKF-77,434 is a D1 receptor partial agonist, meaning it binds to and activates the D1 receptor, but not to its full capacity. This is in contrast to a full agonist, which fully activates the receptor it binds to. The D1 receptor is one of five subtypes of dopamine receptors and is associated with cognitive and motor function.

Potential Therapeutic Uses[edit]

Research has suggested that SKF-77,434 may have potential use in the treatment of Parkinson's disease. Parkinson's disease is a neurodegenerative disorder characterized by the death of dopamine-producing cells in the brain. By acting as a D1 receptor partial agonist, SKF-77,434 could potentially help to alleviate some of the symptoms of Parkinson's disease by increasing dopamine activity in the brain.

Related Compounds[edit]

SKF-77,434 is structurally related to the drug Fenoldopam, a full D1 receptor agonist that is used to treat hypertension. However, the two drugs have different mechanisms of action, with Fenoldopam acting as a full agonist and SKF-77,434 acting as a partial agonist.

See Also[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.